Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and end-stage renal disease. DKD develops in around 40% of patients with type 2 diabetes mellitus (T2DM) and 30% of patients with type 1 diabetes (T1D).1 It is a progressive condition marked by declining kidney function and increased albumin in the urine. The use of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) is essential, even in patients who may not show overt symptoms like proteinuria. Tight glycemic control, blood pressure management, and renin-angiotensin system (RAS) blockade using angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are crucial to slow the progression of DKD.